ADPT vs GH
ADPT: Adaptive Biotechnologies uses its proprietary immune medicine platform to decode the human immune system for cancer diagnostics and drug discovery. GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
Side-by-side fundamentals
| Metric | ADPT | GH | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $25.33 | $166.66 | |
| Market cap | $4.0B | $22.4B | |
| Net margin FY2025, SEC XBRL | -21.5% | -42.4% | ADPT higher |
| Operating margin FY2025, SEC XBRL | -20.6% | -44.5% | ADPT higher |
| ROE FY2025, SEC XBRL | -27.2% | n/a | |
| ROA FY2025, SEC XBRL | -11.6% | -20.7% | ADPT higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +54.8% | +32.9% | ADPT higher |
| Revenue CAGR (3y) SEC XBRL | +14.3% | +29.8% | GH higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.62 | 1.23 | |
| 1-year return as of 2026-10-21 close | +46.0% | +146.9% | GH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.